DHR vs A vs ILMN Stock Comparison

Danaher, Agilent Technologies and Illumina Prices as of Nov 13, 2026 Peers: Industry group
DHR Danaher Corp /De/
$233.03 +3.7% 1M +5.3% 1Y
Market cap
$163.36B
P/E
37.7x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
A Agilent Technologies, Inc.
$173.91 -0.1% 1M +18.4% 1Y
Market cap
$48.80B
P/E
33.9x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
3 wins
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$30.45B
P/E
34.0x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
5 wins

Head to Head

11 decided of 12

Illumina leads on 5 of the 12 questions below (Illumina 5, Danaher 3, Agilent Technologies 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRAILMNLeader
Larger companyMarket capitalisation $163.36B $48.80B $30.45B DHR
Cheaper on earningsLower P/E, profitable companies only 37.7x 33.9x 34.0x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.6x 26.6x 40.9x DHR
Faster revenue growthRevenue growth, trailing twelve months +5.5% +8.6% +5.8% A
More profitableNet margin, trailing twelve months 16.9% 19.5% 19.7% ILMN
Better return on capitalReturn on invested capital 5.8% 13.1% 16.6% ILMN
Less leveragedLower net debt / EBITDA 2.6x 1.1x 0.4x ILMN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% –
Better 1-year returnPrice return, last 12 months +5.3% +18.4% +72.6% ILMN
Better 5-year returnAnnualised price return, 5 years -5.2%/yr +1.6%/yr -11.1%/yr A
Less volatileAnnualised volatility, 1 year 31.0% 32.8% 51.1% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 61/100 75/100 ILMN

Percentile Scorecard

DHRAILMN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRAILMN
Valuation 69 #76 of 243 60 #98 of 243 63 #91 of 243
Growth 25 #172 of 228 37 #144 of 228 73 #63 of 228
Profitability 86 #32 of 222 93 #17 of 222 98 #5 of 222
Financial Health 47 #133 of 248 53 #117 of 248 57 #107 of 248
Shareholder Returns 73 #44 of 158 64 #57 of 158 85 #25 of 158
Overall 60 61 75
  • DHR ranked among 252 companies in Medical Devices and Diagnostics
  • A ranked among 252 companies in Medical Devices and Diagnostics
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRAILMNSPY
1 month +3.7%-0.1%-23.8% -2.0%
3 months +15.1%+17.1%+8.4% -2.8%
6 months +43.9%+55.7%+45.2% +2.0%
Year to date +1.8%+27.8%+57.8% +10.6%
1 year +5.3%+18.4%+72.6% +12.2%
3 years +14.5%+55.8%+118.3% +68.1%
3 years, per year +4.6%+15.9%+29.7% +18.9%
5 years -23.4%+8.1%-44.5% +61.4%
5 years, per year -5.2%+1.6%-11.1% +10.1%
10 years +187.9%+275.0%+54.5% +248.5%
10 years, per year +11.2%+14.1%+4.4% +13.3%

Risk

MeasureDHRAILMNSPY
Volatility, 1Y 31.0%32.8%51.1% 13.6%
Downside volatility, 1Y 32.4%28.1%50.9% 13.9%
Beta vs S&P 500, 1Y 0.550.911.11 1.00
Return / volatility, 1Y 0.170.561.42 0.90
Max drawdown, 5Y -50.8%-39.6%-82.9% -25.4%
From 52-week high -3.7%-4.2%-29.5% -3.2%
52-week high $242.05$181.54$293.69 $779.14
52-week low $161.91$110.24$114.44 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRAILMN
P/E now vs peer median 37.9xmedian 26.5x 34.1xmedian 26.5x 34.9xmedian 26.5x
P/S now vs peer median 6.4xmedian 2.7x 6.7xmedian 2.7x 6.9xmedian 2.7x
EV/EBITDA now vs peer median 23.5xmedian 18.4x 26.8xmedian 18.4x 25.7xmedian 18.4x
P/FCF now vs peer median 28.6xmedian 25.4x 38.7xmedian 25.4x 29.6xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 6.7xmedian 2.5x 10.0xmedian 2.5x
PEG now vs peer median -4.72median 0.98 3.46median 0.98 0.85median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRAILMN
Revenue $25.61B $7.37B $4.54B
Gross profit $15.01B $3.97B $3.08B
Operating income $5.22B $1.64B $960.00M
Net income $4.33B $1.44B $895.00M
Free cash flow $5.73B $1.27B $1.06B
R&D $1.67B $485.00M $975.00M
EPS (diluted) $6.13 $5.09 $5.81
Cash & equivalents $5.68B $1.76B $1.29B
Total debt $26.48B $3.95B $1.79B
Shares (diluted) 706.80M 283.00M 154.00M
Enterprise value $143.01B $41.69B $25.16B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRAILMN
P/E 37.9x 34.1x 34.9x
P/FCF 28.6x 38.7x 29.6x
P/Operating cash flow 23.9x 30.5x 25.4x
P/S 6.4x 6.7x 6.9x
P/B 3.1x 6.7x 10.0x
P/Tangible book 5.0x 7.6x 11.4x
EV/EBITDA 23.5x 26.8x 25.7x
EV/EBIT 35.4x 31.3x 33.1x
EV/Revenue 7.2x 6.9x 7.0x
EV/FCF 32.3x 40.4x 30.0x
EV/Operating cash flow 26.9x 31.8x 25.8x
PEG (3Y EPS CAGR) -4.72 3.46 0.85

Growth

14 metrics
MetricDHRAILMN
Revenue growth (1Y) 5.5% 8.6% 5.8%
Revenue CAGR (3Y) 1.3% 1.8% -0.7%
Gross profit growth (1Y) 3.9% 11.2% 8.5%
Gross profit CAGR (3Y) 1.2% 3.7% 4.4%
Operating income growth (1Y) 13.1% 13.5% 23.1%
Operating income CAGR (3Y) -3.8% 5.1% 30.0%
Net income growth (1Y) 23.6% 18.0% 27.5%
Net income CAGR (3Y) -9.9% 8.3% 40.9%
EPS growth (1Y) 24.8% 18.9% 27.5%
EPS CAGR (3Y) -8.0% 9.8% 41.2%
Operating cash flow growth (1Y) 8.6% 7.6% 9.6%
Operating cash flow CAGR (3Y) -5.3% -1.9% 47.5%
Free cash flow growth (1Y) 14.2% 16.5% 5.7%
Free cash flow CAGR (3Y) -5.8% -3.7% 126.5%

Profitability

14 metrics
MetricDHRAILMN
Gross margin 58.6% 53.8% 67.9%
EBITDA margin 30.7% 25.9% 27.3%
Operating margin 20.4% 22.2% 21.2%
Pretax margin 18.8% 22.5% 23.3%
Net margin 16.9% 19.5% 19.7%
FCF margin 22.4% 17.2% 23.3%
Operating cash flow margin 26.8% 21.8% 27.1%
Return on equity 8.2% 19.9% 29.9%
Return on assets 4.7% 10.7% 13.3%
Return on invested capital 5.8% 13.1% 16.6%
Return on capital employed 6.2% 14.6% 17.2%
Asset turnover 0.3x 0.5x 0.7x
Cash conversion (OCF / net income) 1.6x 1.1x 1.4x
Stock comp / revenue 1.3% 1.8% 5.9%

Financial Health

11 metrics
MetricDHRAILMN
Debt / assets 28.4% 28.3% 26.3%
Debt / equity 0.5x 0.5x 0.6x
Net debt / EBITDA 2.6x 1.1x 0.4x
Debt / FCF 4.6x 3.1x 1.7x
Liabilities / assets 42.5% 47.3% 53.8%
Equity / assets 57.5% 52.7% 46.2%
Interest coverage 14.5x 15.5x 9.8x
Current ratio 1.6x 2.1x 2.6x
Quick ratio 1.1x 1.4x 1.8x
Cash ratio 0.6x 0.8x 1.2x
Altman Z-score 3.75 5.77 6.62

Shareholder Returns

7 metrics
MetricDHRAILMN
Dividend yield 0.7% 0.6% –
Net buyback yield 0.5% 0.6% 1.2%
Shareholder yield 1.1% 1.2% 1.2%
Payout ratio (earnings) – 19.9% –
Payout ratio (FCF) – 22.6% –
Dividend growth (1Y) – 2.1% –
Dividend CAGR (3Y) – 3.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRAILMN
Forward P/E 25.6xFY2026 26.6xFY2026 40.9xFY2026
EPS, next fiscal year $9.12FY2026 $6.54FY2026 $5.06FY2026
EPS growth, next FY +16.9%FY2026 +17.0%FY2026 +4.5%FY2026
EPS growth, the year after +7.9% +0.2% +25.1%
Revenue, next fiscal year $27.01BFY2026 $7.87BFY2026 $4.53BFY2026
Revenue growth, next FY +9.9%FY2026 +15.3%FY2026 +4.4%FY2026
Revenue growth, the year after -1.9% -5.6% +12.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRAILMN
Held by institutions 81.9% 92.6% 100.0%
Institutions holding 2,121 1,126 935
Change in shares held, QoQ +1.1% +3.2% +0.0%
Institutions buying 841 601 464
Institutions selling 1,016 351 331
Buyers to sellers 0.83 1.71 1.40

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRAILMN
DHR 1.00 0.62 0.38
A 0.62 1.00 0.51
ILMN 0.38 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, A and ILMN?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $163.36B, Agilent Technologies (A) $48.80B, Illumina (ILMN) $30.45B.

Which stock is cheaper, DHR, A and ILMN?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Danaher (DHR) 37.7x, Agilent Technologies (A) 33.9x, Illumina (ILMN) 34.0x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.6x, Agilent Technologies (A) 26.6x, Illumina (ILMN) 40.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Danaher (DHR) +5.5%, Agilent Technologies (A) +8.6%, Illumina (ILMN) +5.8%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Danaher (DHR) 16.9%, Agilent Technologies (A) 19.5%, Illumina (ILMN) 19.7%). On return on invested capital, Illumina (ILMN) leads (Danaher (DHR) 5.8%, Agilent Technologies (A) 13.1%, Illumina (ILMN) 16.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Danaher (DHR) +5.3%, Agilent Technologies (A) +18.4%, Illumina (ILMN) +72.6%. Over five years, Agilent Technologies (A) compounded fastest (Danaher (DHR) -5.2%/yr, Agilent Technologies (A) +1.6%/yr, Illumina (ILMN) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Agilent Technologies (A) 0.01%, Illumina (ILMN) 0.00%. Danaher (DHR) and Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 31.0%, Agilent Technologies (A) 32.8%, Illumina (ILMN) 51.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, A and ILMN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.